non-HDL cholesterol fasting state
Selected indexed studies
- Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. (Atherosclerosis, 2023) [PMID:37826864]
- Lipid Profile and Lipoprotein(a) Testing. (Dtsch Arztebl Int, 2023) [PMID:37403458]
- Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. (N Engl J Med, 2024) [PMID:38809174]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. (2023) pubmed
- The association between non-HDL cholesterol and high-grade pancreatic neuroendocrine neoplasms. (2024) pubmed
- Non-HDL/HDL cholesterol ratio (NHHR) as a novel predictor of gestational diabetes mellitus: a NHANES-based cross-sectional study. (2025) pubmed
- Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. (2016) pubmed
- Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments. (2023) pubmed
- Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. (2024) pubmed
- Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. (2024) pubmed
- Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. (2019) pubmed
- Lipid Profile and Lipoprotein(a) Testing. (2023) pubmed
- Childhood Non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events. (2024) pubmed